Tower Research Capital (TRC)’s Genocea Biosciences, Inc. GNCA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-5,847
Closed -$7K 7092
2022
Q1
$7K Sell
5,847
-211
-3% -$230 ﹤0.01% 4832
2021
Q4
$7K Buy
6,058
+156
+3% +$232 ﹤0.01% 5000
2021
Q3
$11K Sell
5,902
-2,672
-31% -$5.25K ﹤0.01% 4296
2021
Q2
$20K Sell
8,574
-328
-4% -$791 ﹤0.01% 3918
2021
Q1
$24K Sell
8,902
-5,991
-40% -$17.7K ﹤0.01% 3758
2020
Q4
$36K Buy
14,893
+13,389
+890% +$30.5K ﹤0.01% 3440
2020
Q3
$3K Buy
+1,504
New +$3.95K ﹤0.01% 4561
2019
Q3
Sell
-1,065
Closed -$4K 4852
2019
Q2
$4K Buy
+1,065
New +$5.56K ﹤0.01% 3099
2018
Q2
Sell
-523
Closed -$5K 4349
2018
Q1
$5K Sell
523
-93
-15% -$772 ﹤0.01% 2754
2017
Q4
$6K Sell
616
-446
-42% -$4.49K ﹤0.01% 2845
2017
Q3
$12K Buy
+1,062
New +$40.3K ﹤0.01% 3016
2017
Q1
Sell
-468
Closed -$15K 4361
2016
Q4
$15K Buy
468
+254
+119% +$8.37K ﹤0.01% 2391
2016
Q3
$9K Buy
+214
New +$8.39K ﹤0.01% 2175
2016
Q1
Sell
-150
Closed -$6K 5356
2015
Q4
$6K Sell
150
-329
-69% -$15.7K ﹤0.01% 2871
2015
Q3
$26K Buy
+479
New +$47.5K ﹤0.01% 1529
2015
Q2
Sell
-278
Closed -$26K 5343
2015
Q1
$26K Buy
278
+235
+547% +$16.6K ﹤0.01% 2052
2014
Q4
$2K Sell
43
-725
-94% -$49.5K ﹤0.01% 3458
2014
Q3
$56K Buy
+768
New +$84.1K 0.01% 1443
2014
Q2
Sell
-84
Closed -$12K 4919
2014
Q1
$12K Buy
+84
New +$10.3K ﹤0.01% 2463

Other funds holding GNCA

Tower Research Capital (TRC)'s GNCA Position: Q2 2022 in Review

Tower Research Capital (TRC) sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 5,847 shares — an estimated $7K sold.

Tower Research Capital (TRC) first reported a position in GNCA in Q1 2014 and held it in 19 quarters. The position peaked at $56K in Q3 2014. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

  • Tower Research Capital (TRC) reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 5,847 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $7K.
  • Tower Research Capital (TRC) first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 19 quarters.
  • Tower Research Capital (TRC)'s Genocea Biosciences, Inc. position peaked at $56K in Q3 2014.
  • 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.